The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Mass Spectrometry Core is a part of the larger institutional Johns Hopkins University School of Medicine (JHUSOM) Mass Spectrometry and Proteomics Facility. It provides SKCCC investigators access at a reduced cost to advanced proteomic services, a designated Core Mass Spectrometrist and a Proteomics Specialist, a specific biostatistician/bioinformatician for post-identification/quantification data analysis. The Mass Spectrometry Core couples multidimensional separations by column chromatography or gel electrophoresis to mass spectrometry analysis. It is used to identify, quantify and characterize proteins and their post-translational modifications expressed in well- characterized protein fractions from cancerous cells, tissues or body fluids. Techniques such as isobaric mass tag labeling (TMT, tandem mass tags, or iTRAQ, isobaric tag for relative and absolute quantitation), stable isotope labeling of amino acids in cell culture (SILAC) and nonlabeling methods (MuDPIT, multidimensional protein identification technology) are available for quantifying relative differences in protein expression and post-translational modifications, such as acetylation, AMPylation, citrullination, glycosylation, phosphorylation, nitrosation, proline hydroxylation, ubiquitination and novel cleavage sites. The Core offers recently established targeted proteomic methods, such as absolute quantification (AQUA) and protein standard absolute quantification (PSAQ) methods, to determine the amount of specific proteins. In addition, the Core offers high-resolution mass and fragmentation analysis of intact proteins?a top down approach to characterize proteins and their modifications. Core services include pre- and post-analysis consultation on sample preparation, data analysis and interpretation; proteolytic digestion, peptide extraction, labeling and fractionation; nanoliquid chromatography separation coupled with tandem mass spectrometry analysis; database searching; compiled results reports; and educational programs through core presentations and technical workshops. A biostatistician/bioinformatician is available when more in-depth statistical and ontological analyses of the proteomic results are needed. When SKCCC investigators wish to perform their own analysis, the Core provides access to proprietary software and equipment. Core workshops on operating the Core MALDI mass spectrometer are offered several times a year. During this funding period, 57 SKCCC investigators have used the Mass Spectrometry Core, and more than 50 manuscripts are attributed to this Core. Jointly SKCCC and Department of Biological Chemistry Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-55
Application #
9519872
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications